Diffusely infiltrative low-grade gliomas in adults

Journal of Clinical Oncology

Volumn 24, Issue 8, 2006, Pages 1236-1245

  Lang, Frederick F ^a   Gilbert, Mark R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADJUVANT THERAPY; ASTROCYTOMA; CANCER GRADING; CANCER INFILTRATION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; HUMAN; MULTIPLE CYCLE TREATMENT; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURGICAL TECHNIQUE; ADULT; CENTRAL NERVOUS SYSTEM TUMOR; GLIOMA; METABOLISM; PATHOLOGY;

ADULT; CENTRAL NERVOUS SYSTEM NEOPLASMS; GLIOMA; HUMANS; PROGNOSIS;

EID: 33644870353     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.2399     Document Type: Review

References (82)

1. Kleihues P, Cavenee WK: Pathology and Genetics of Tumors of the Nervous System. Lyon, France, IARC Press, 2000, p 9-70
2. Sackett DL: Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 95:2S-4S, 1989
3. Burger PC: What is an oligodendroglioma? Brain Pathol 12:257-259, 2002
4. Pignatti F, van den Bent M, Curran D, et al: Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:2076-2084, 2002
5. Cairncross G, Macdonald D, Ludwin S, et al: Chemotherapy for anaplastic oligodendroglioma: National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12:2013-2021, 1994
6. CBTRUS: Statistical Report: Primary Brain Tumors in the United States, 1995-1999. Chicago, IL, Central Brain Tumor Registry of the United States, 2002
7. Sasaki H, Zlatescu MC, Betensky RA, et al: Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma." J Neuropathol Exp Neurol 61:58-63, 2002
8. McDonald JM, See SJ, Tremont IW, et al: The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer 104: 1468-1477, 2005
9. Ino Y, Betensky RA, Zlatescu MC, et al: Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis. Clin Cancer Res 7:839-845, 2001
10. Cairncross JG, Ueki K, Zlatescu MC, et al: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479, 1998
11. Bauman GS, Ino Y, Ueki K, et al: Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 48:825-830, 2000
12. Bigner SH, Matthews MR, Rasheed BK, et al: Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 155:375-386, 1999
13. Ino Y, Zlatescu MC, Sasaki H, et al: Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg 92:983-990, 2000
14. Ashby LS, Shapiro WR: Low-grade glioma: Supratentorial astrocytoma, oligodendroglioma, and oligoastrocytoma in adults. Curr Neurol Neurosci Rep 4:211-217, 2004
15. Ellis TL, Stieber VW, Austin RC: Oligodendroglioma. Curr Treat Options Oncol 4:479-490, 2003
16. Fallon KB, Palmer CA, Roth KA, et al: Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 63:314-322, 2004
17. Smith JS, Perry A, Borell TJ, et al: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636-645, 2000
18. van den Bent MJ: Advances in the biology and treatment of oligodendrogliomas. Curr Opin Neurol 17:675-680, 2004
19. van den Bent MJ, Looijenga LH, Langenberg K, et al: Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 97:1276-1284, 2003
20. Okamoto Y, DiPatre PL, Burkhard C, et al: Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropath 108:49-56, 2004
21. Hoang-Xuan K, Capelle L, Kujas M, et al: Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22:3133-3138, 2004
22. Buckner JC, Gesme D Jr, O'Fallon JR, et al: Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: Efficacy and associations with chromosomal abnormalities. J Clin Oncol 21:251-255, 2003
23. Stege EM, Kros JM, de Bruin HG, et al: Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 103:802-809, 2005
24. Lang F, Miller DC, Pisharody S, et al: High frequency of p53 protein acumulatin without p53 gene mutation in human pilocytic astrocytoma, low grade glioma, and anaplastic astrocytomas. Oncogene 9:949-954, 1994
25. Pollack IF, Finkelstein SD, Woods J, et al: Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 346:420-427, 2002
26. Janny P, Cure H, Mohr M, et al: Low grade supratentorial astrocytomas: Management and prognostic factors. Cancer 73:1937-1945, 1994
27. Leighton C, Fisher B, Bauman G, et al: Supratentorial low-grade glioma in adults: An analysis of prognostic factors and timing of radiation. J Clin Oncol 15:1294-1301, 1997
28. Lote K, Egeland T, Hager B, et al: Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: A retrospective study in 379 patients. J Clin Oncol 15:3129-3140, 1997
29. Reichenthal E, Feldman Z, Cohen ML, et al: Hemispheric supratentorial low-grade astrocytoma. Neurochirurgia (Stuttg) 35:18-22, 1992
30. Shibamoto Y, Kitakabu Y, Takahashi M, et al: Supratentorial low-grade astrocytoma: Correlation of computed tomography findings with effect of radiation therapy and prognostic variables. Cancer 72: 190-195, 1993
31. Vecht CJ: Effect of age on treatment decisions in low-grade glioma. J Neurol Neurosurg Psychiatry 56:1259-1264, 1993
32. Quinn JA, Reardon DA, Friedman AH, et al: Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 21:646-651, 2003
33. van den Bent MJ, Afra D, de Witte O, et al: Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: The EORTC 22845 randomised trial. Lancet 366:985-990, 2005
34. Keles GE, Lamborn KR, Berger MS: Low-grade hemispheric gliomas in adults: A critical review of extent of resection as a factor influencing outcome. J Neurosurg 95:735-745, 2001
35. Berger MS, Deliganis AV, Dobbins J, et al: The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 74:1784-1791, 1994
36. Bernstein M, Guha A: Biopsy of low grade astrocytomas. J Neurosurg 80:776-777, 1994
37. Hentschel SJ, Lang FF: Current surgical management of glioblastoma. Cancer J 9:113-125, 2003
38. Toms S, Ferson D, Sawaya R: Basic surgical techniques in the resection of malignant gliomas. J Neurooncol 42:215-226, 1999
39. Barnett G: The role of image-guided technology in the surgical planning and resectin of gliomas. J Neurooncol 42:247-258, 1999
40. Duffau H, Lopes M, Arthuis F, et al: Contribution of intraoperative electrical stimulations in surgery of low grade gliomas: A comparative study between two series without (1985-96) and with (1996-2003) functional mapping in the same institution. J Neurol Neurosurg Psychiatry 76:845-851, 2005
41. Claus EB, Horlacher A, Hsu L, et al: Survival rates in patients with low-grade glioma after intra-operative magnetic resonance image guidance. Cancer 103:1227-1233, 2005
42. Sawaya R, Hammoud M, Schoppa D, et al: Neurosurgical outcomes in a series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 42:1044-1056, 1998
43. Jackson R, Fuller G, Abi-Said D, et al: Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-Oncology 3:193-200, 2001
44. Lupo JM, Cha S, Chang SM, et al: Dynamic-susceptibility-weighted perfusion imaging of high grade gliomas: Characterization of spacial heterogeneity. Am J Neuroradiol 26:1446-1454, 2005
45. Cha S: Update on brain tumor imaging. Cur Neurol Neurosci Rep 5:169-177, 2005
46. Inoue T, Ogasawara K, Beppu T, et al: Diffusion tensor imaging for preoperative evaluation of tumor grade in gliomas. Clin Neurol Neurosurg 107: 174-180, 2005
47. Go KG, Keuter EJ, Kamman RL, et al: Contribution of magnetic resonance spectroscopic imaging and L-[1-11C]tyrosine positron emission tomography to localization of cerebral gliomas for biopsy. Neurosurgery 34:994-1002, 1994; discussion 1002
48. Son BC, Kim MC, Choi BG, et al: Proton magnetic resonance chemical shift imaging (1H CSI)-directed stereotactic biopsy. Acta Neurochir (Wien) 143:45-49, 2001; discussion 49-50
49. Ammirati M, Vick N, Liao YL, et al: Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery 21:201-206, 1987
50. Keles GE, Aldape K, Berger MS: Low-grade gliomas: Astrocytoma, oligodendroglioma, and mixed gliomas, in Winn HR (ed): Youmans Neurological Surgery (5th ed). Philadelphia, PA, WB Saunders Co, 2004, pp 950-968
51. Stummer W, Novotny A, Stepp H, et al: Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: A prospective study in 52 consecutive patients. J Neurosurg 93:1003-1013, 2000
52. Vuorinen V, Hinkka S, Farkkila M, et al: Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir (Wien) 145:5-10, 2003
53. McCormack BM, Miller DC, Budzilovich GN, et al: Treatment and survival of low-grade astrocytoma in adults-1977-1988. Neurosurgery 31:636-642, 1992; discussion 642
54. Yeh SA, Ho JT, Lui CC, et al: Treatment outcomes and prognostic factors in patients with supratentorial low-grade gliomas. Br J Radiol 78: 230-235, 2005
55. Shi W, Wildrick DM, Sawaya R: Volumetric measurement of brain tumors from MR imaging. J Neurooncol 37:87-93, 1998
56. Albert FK, Forstin M, Sartor K, et al: Early postoperative magnaetic imaging after resection of malignant glioma: Objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 34:45-61, 1994
57. Schmidt MH, Berger MS, Lamborn KR, et al: Repeated operations for infiltrative low-grade gliomas without intervening therapy. J Neurosurg 98: 1165-1169, 2003
58. Jeremic B, Shibamoto Y, Grujicic D, et al: Hyperfractionated radiation therapy for incompletely resected supratentorial low-grade glioma: A phase II study. Radiother Oncol 49:49-54, 1998
59. Shaw EG: Low-grade gliomas: To treat or not to treat? A radiation oncologist's viewpoint. Arch Neurol 47:1138-1140, 1990
60. Papagikos MA, Shaw EG, Stieber VW: Lessons learned from randomised clinical trials in adult low grade glioma. Lancet Oncol 6:240-244, 2005
61. Karim AB, Maat B, Hatlevoll R, et al: A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 36:549-556, 1996
62. Shaw E, Arusell R, Scheithauer B, et al: Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: Initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 20:2267-2276, 2002
63. Karim AB, Afra D, Cornu P, et al: Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4 - An interim analysis. Int J Radiat Oncol Biol Phys 52:316-324, 2002
64. DeAngelis LM, Dalattre J-Y, Posner JB: Radiation-induced dementia in patients cured of brain metastases. Neurology 39:789-796, 1989
65. Meyers CA, Brown PD: Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol 24:1305-1309, 2006
66. Brown PD, Buckner JC, O'Fallon JR, et al: Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination. J Clin Oncol 21:2519-2524, 2003
67. Olson JD, Riedel E, DeAngelis LM: Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 54:1442-1448, 2000
68. Brada M, Viviers L, Abson C, et al: Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 14:1715-1721, 2003
69. Mason WP, Krol GS, DeAngelis LM: Low-grade oligodendroglioma responds to chemotherapy. Neurology 46:203-207, 1996
70. Soffietti R, Ruda R, Bradac GB, et al: PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 43:1066-1073, 1998
71. Pace A, Vidiri A, Galie E, et al: Temozolomide chemotherapy for progressive low-grade glioma: Clinical benefits and radiological response. Ann Oncol 14:1722-1726, 2003
72. van den Bent MJ, Chinot O, Boogerd W, et al: Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 14:599-602, 2003
73. Eyre HJ, Crowley JJ, Townsend JJ, et al: A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: A Southwest Oncology Group study. J Neurosurg 78:909-914, 1993
74. van den Bent MJ: Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies. Semin Oncol 30:39-44, 2003
75. Levin VA, Edwards MS, Wright DC, et al: Modified procarbazine, CCNU, and vincristine IPCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 64:237-244, 1980
76. Cairncross G, Seiferfeld W, Shaw E, et al: A phase III intergroup randomized comparison of radiation alone vs pre-radiation intensive-PCV for pure and mixed anaplastic oligodendrogliomas. J Clin Oncol 22:107s, 2004 (suppl; abstr 1500)
77. van den Bent M, Delattre JY, Brandes AA, et al: EORTC 26951: Phase III study of adjuvant PCV in patients with highly anaplastic oligodendroglioma. J Clin Oncol 23: 114s, 2005 (abstr 1503)
78. Jaeckel KA, Ballman KV, Rao RD, et al: Current Strategies in Treatment of Oligodendroglioma: Evolution of Molecular Signatures of Response, J Clin Oncol 24:1246-1252, 2006
79. Yung WK, Prados MD, Yaya-Tur R, et al: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse: Temodal Brain Tumor Group. J Clin Oncol 17:2762-2771, 1999
80. Yung WK, Albright RE, Olson J, et al: A phase Il study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588-593, 2000
81. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
82. Lang FF, Olansen NE, DeMonte F, et al: Surgical resection of intrinsic insular tumors: Complication avoidance. J Neurosurg 95:638-650, 2001